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Nasal nitric oxide is a marker of poor 
asthma control 
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Abstract 
 
Asthma control, evaluated by symptoms, exacerbations rate and lung function may be greatly influenced by 
comorbidities, particularly chronic rhinosinusitis (CRS). Measurement of nasal nitric oxide (nNO) is a simple way to 
assess the severity of CRS. We aimed to analyze the relationship between asthma control and nasal  NO. All patients 
with moderate-to-severe asthma on regular follow-up  at our Outpatients’ Clinic between November 2009 and April 
2010 were included into the study. All patients were evaluated for asthma control by asthma control questionnaire 
(ACQ) and comorbidities (rhinitis, chronic rhinosinusitis with (CRSwNP) or without nasal polyps, obesity). Exhaled 
nitric oxide and nNO were obtained in all patients. Eighty-two patients were enrolled (mean age: 48 years, range: 21–80; 
42 females).  According to ACQ, 53 patients (64.6%) reported  controlled asthma. Patients with uncontrolled asthma had 
lower nNO and higher prevalence of CRSwNP, with a significant correlation between nNO and ACQ. nNO is a 
biomarker negatively related to asthma control. As low nNO values were associated to CRSwNP, our results indicate that 
asthma control is highly influenced by this comorbidity. 
 
 
Introduction 
 
Asthma    is    a    chronic    inflammatory   airway    disease characterized by airway hyper-responsiveness and   
reversible bronchial obstruction [1]. Based on this definition, current asthma   therapy   is   based   on   a    variable    
combination of  anti-inflammatory (mainly  inhaled  corticosteroids)  and bronchodilating  drugs.  Asthma  guidelines  
recommend  to modulate the therapy according to asthma control, defined as patient’s current and recent level of 
symptoms and functional status. Many data support the recommendation that having a high level of current control 
improves stability and reduces the risk of exacerbations [2]. Easy-to-administer questionnaires have been developed 
in recent years to help clinicians to monitor asthma control of their patients. Among the most used 
questionnaires are asthma control test (ACT) [3] and asthma control questionnaire (ACQ) [4]. Both questionnaires 
explore patients’ symptoms, referred to the last four weeks in case of ACT and for the last week in case of ACQ, for 
which FEV1 measurement is also required. Nevertheless, even among patients treated according to guidelines, control of 
asthma is still not reached by a great proportion of patients, ranging from 20% to 70% [5].  
Different asthma comorbidities may impact on asthma control, worsening symptoms and/or contributing to 
airway inflammation.  Among  the   most  frequently  encountered comorbid conditions associated to asthma are 
rhinosinusitis, gastro-esophageal reflux disease and obesity.  
With respect to chronic rhinosinusitis, it has been reported that  90%  of  patients  with  mild  to  moderate  
asthma  and almost 100% of those with severe asthma, have radiological abnormalities of the sinuses [6]. Chronic 
rhinosinusitis has been associated with both more severe and more difficult to  control  asthma  [7]  and  ten  
Brinke  et  al  [8]  found extensive sinus disease associated with eosinophilic airway inflammation in 24% of patients 
with severe asthma.  
Low  values  of  nasal  NO  (nNO)  have  been  reported in  patients  with  chronic  rhinosinusitis  with  nasal  
polyps (CRSwNP) [9, 10], and damage of the ciliated epithelium of the paranasal sinuses and the size of the 
paranasal sinus ostia have been suggested as explanatory mechanisms. An inverse relationship between nNO 
concentration and the extent of sinus disease, as documented by CT, was observed [11]. For these reasons, we wished to 
measure nNO as a marker of sinus involvement in asthmatic patients and to test its relationship with asthma control.  
To   this   aim   we   investigated   the   determinants   of uncontrolled  asthma  by  evaluating  the  relative  
role  of the most common asthma co-morbidities (rhinitis, chronic rhinosinusitis  with  (CRSwNP)  and  without  
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nasal  polyps (CRSsNP),  obesity)  and  non-invasive  markers  of  sinus involvement (nNO) and airway 
inflammation (exhaled nitric oxide (FENO) and its alveolar concentration (CalvNO) and bronchial flux (JawNO)).  
 
 
 
 
 
 
Methods 
Patients 
Eighty-two non-smoking consecutive patients (42 women) aged 21–80 years (mean age 48 years) with previously 
diagnosed moderate-to-severe asthma according to GINA international guidelines [1] and in regular follow-up at 
Outpatient Asthma Clinic of AO Mauriziano ‘Umberto I’ Hospital of Turin between November 2009 and April 2010 
(six months) were included into the study. 
 
 
All the patients were queried regarding symptoms of rhinitis and underwent skin prick to a panel of 14 
common inhalant allergens. Atopy was defined as the  presence  of at least one positive skin prick test (wheal 
diameter >3 mm compared  to  negative  control)  to  inhalant  allergens.  All the patients complaining of nasal 
blockage/obstruction  and discolored discharge or reduction in sense of smell or facial pain/pressure  for >3 
months were referred to an ear, nose and throat specialist for nasal endoscopy and/or CT scan of the sinuses. 
CRS was confirmed by the presence of two of the above-mentioned symptoms and endoscopic signs (polyps, 
mucopurulent discharge from middle meatus, edema/mucosal obstruction primarily in middle meatus) and/or CT 
signs of mucosal changes within ostiomeatal complex and/or sinuses [12]. Using previously published Lund–
Mackay cutoff scores of 2 or more, cases were classified based on the radiographic extent of disease in patients 
with and without CRS [13]. 
Body mass index (BMI) was calculated in every patient. None  of  the  enrolled  patients  were  using  intranasal 
corticosteroids. 
Forty non-smoking subjects, matched for age, served as control for nitric oxide measurements. All patients and 
controls gave their written consent to participate to the study, which was approved by local Ethics Committee  
(Comitato Etico Interaziendale N: 146/2009). 
 
Exhaled nitric oxide 
 
Exhaled NO was measured at 50, 100 and 200 ml s−1 with a chemiluminescence analyzer (NIOX, Aerocrine AB, 
Solna, Sweden), according to current recommendations [14]. 
NO output was plotted against exhalation flow rate at flow rates 50–200 ml s–1, and a regression line was set between 
these variables. All subjects had a correlation coefficient >0.95 in the regression analysis. Alveolar NO concentration 
(CalvNO) and bronchial NO flux (JawNO) are the slope and intercept of the regression line, respectively [15]. 
Axial   backward   diffusion   of   NO   from   bronchial compartment to alveoli may cause falsely high  CalvNO  
and falsely low JawNO especially in subjects with increased JawNO. CalvNO and JawNO adjusted for trumpet-shaped 
airways and axial diffusion (CalvNO [TMAD] and JawNO [TMAD]) were calculated according to the equations 
described by Condorelli et al [16]. 
 
Nasal nitric oxide 
 
Measurements      were      obtained      using      the      same chemiluminescence  NO  analyzer  (NIOX;   Aerocrine   
AB, Solna, Sweden) calibrated with a certified NO calibration gas mixture according to European Respiratory 
Society/American Thoracic Society recommendations [14]. The patients were relaxed and in a sitting position. They 
were asked to insert a NIOX nasal olive into one nostril. They then inhaled to total lung capacity for more than 2 to 
3 s through open mouths, after which they closed their mouths and held their breath while NO  was continuously 
measured at an aspiration flow rate of 5 ml s−1.  
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We took into consideration the NO levels that were recorded at the plateau, which occurs after 20 to 30 s in most 
patients. The nasal olive was then placed in the other nostril and the test was repeated. Measurements were made in 
triplicate on both nostrils, and the highest mean value, from which the ambient NO level was subtracted, was 
considered. 
 
Assessment of asthma control by ACQ 
ACQ 
It  consists  of  seven  items:  six  questions,  five related  to symptoms during the last week and one related to 
the use of short-acting beta2 agonists, and the seventh item is an objective measure—a spirometric assessment 
(FEV1% predicted). Each item has seven alternatives of answer, scored from 0 to 6. The ACQ score is the 
mean of all these individual answers and therefore, it ranges also from 0 to 6 with higher scores standing for 
poorer control of asthma. A score of  ≤ 0.75 has been associated with ‘well-controlled’ asthma while a score 
≥1.5 has been associated with ‘not well-controlled’ asthma 
[4]. 
 
Lung function 
 
Measurements of  lung  function were  done  with  a  water-  sealed  spirometer  (Biomedin,  Padua,  Italy).  
The  best  of three measurements was automatically chosen by software. The parameters of interest were 
FEV1, FEV1/FVC  ratio%, FEF25–75%. 
Statistics 
Statistical analyses were performed using SPSS 16.0 software (SPSS, Chicago, IL, USA).  
The Kolmogorov–Smirnov test was used to evaluate the normality of distribution of each continuous 
variable, and depending on the result of this test, the Student t-test or Mann– Whitney test were used to compare 
variables. Categorical variables were compared with the Fisher exact test.  
Values are presented as mean (95% confidence interval). Stepwise multiple regression analysis has been 
performed to  evaluate  the  effect  of  demographical,  physical  and inflammatory variables (age, gender, atopy, 
BMI, budesonide  equivalent of inhaled corticosteroid therapy, FENO and nNO)  
on ACT and ACQ values as dependent variables. Correlations between any significant determinant of asthma  control 
and known comorbidities have been evaluated.  
A   p-value   of   <0.05   was   considered   statistically significant. 
 
Results 
Eighty-two patients with a diagnosis of moderate-to-severe asthma  were  enrolled  (mean  age  48  years,  range  
21–80; 42 females; mean BMI 24.1 ± 2.9; 1 smoker; 4 with NSAID intolerance). 
Demographic  data,  lung  function  and  nitric  oxide parameters obtained in patients and controls are 
summarized in table 1.  Atopy prevalence was higher in patients with asthma than in healthy controls (75.6%  
versus 20% p < 0.001). Spirometric parameters were  significantly reduced in patients compared to controls 
(table 1). Mean  values of FENO, JawNO and CalvNO were significantly higher while nNO oxide values were  
significantly lower in patients than controls (table 1). According  to  ACQ  (ACQ≤1.5),  54  patients  (65.8%) 
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reported  controlled  asthma  (table  2).  Mean  nNO  was significantly lower in patients with non-controlled  
asthma, ACQ>1.5 (481.6 ± 390.6 ppb versus 705.1 ± 405.2 ppb, p = 0.018), who showed a higher  prevalence  
of CRSwNP compared to patients with ACQ ≤ 1.5 (16/28, 57.1% versus 18/54, 33.3%, p = 0.038).  
Patients with CRSwNP had significantly higher ACQ values (1.36  ± 1.04) compared to patients with  
CRSsNP (0.66   ±  0.62,  p  = 0.033)  and  patients  without  CRS (0.53 ± 0.62, p < 0.001).  
No significant correlation between mean responses to any of the seven items of ACQ and nNO levels and/or 
presence of nasal polyps was found.  
Median Lund–Mackay CT score was significantly higher in patients with CRSwNP (13, 95%IC: 8–20)  
compared to patients with CRSsNP (3, 95%IC: 2–5, p < 0.001) and to those without CRS (1, 95%IC: 0–1,  
p < 0.001).  
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Patients with CRSwNP had significantly lower values of nNO (311.0  ± 221.0 ppb) compared to the other 
patients (853.9 ± 365.2 ppb) and to controls (887.5 ± 252.0) (p < 0.001) (figure 1). A significant correlation was 
found between nNO and ACQ (R2 = 0.253, p = 0.002) in patients with CRS (figure 2).  
No difference in mean values of FENO  was detectable between patients with CRSwNP versus CRSsNP and/or 
versus patients without CRS.  
Multiple regression analysis (table 3) with age, gender, atopy, BMI, equivalents of inhaled budesonide, FENO, 
JawNO, CalvNO and nNO as independent variables showed that nNO was the only significant determinant of poor 
asthma control (p = 0.008).  
Smoking  status  and  non-steroidal  anti-inflammatory drugs  (NSAIDs)  intolerance  were  not  included  into  
the analysis  as  only  a  minority  of  patients  reported  these characteristics  (only  one  smoker  patient  with  
controlled asthma,   and   four   NSAIDs   intolerant   patients   equally distributed  between  controlled  and  
uncontrolled   asthma groups). 
Discussion 
The main result of our study is that low nNO values, which are significantly associated to CRSwNP, are also 
significantly correlated to asthma control as assessed by ACQ. The best explanation for the inverse relation between 
nNO and asthma control may be the high prevalence of CRS in our population of asthmatics (41.5%). It is known that 
CRS is a comorbidity which may negatively influence the severity and control of asthma [6, 17, 18]. Nasal NO levels 
have been reported to be greatly influenced by the degree of sinus involvement, with an inverse correlation between 
nNO levels and the extent of sinus disease as documented by CT scan, endoscopic score and polyp grades [11, 19]. So 
it is not surprising that the inverse relationship between nNO and asthma control was even more significant in our 
patients with CRS, suggesting that severe CRS has a major impact on asthma control.  
On  the  other  hand,  we  did  not  find  any  significant correlation  between  FENO   and  asthma  control.  The  
lack of correlation between FENO  and asthma control has been previously reported both in adults and children [20–
22]. A weak correlation between asthma control, evaluated with ACT, and FENO was described by Japanese authors 
in a cohort of 105 patients with a high prevalence of uncontrolled asthma (60%) [23]. A better correlation between 
FENO and childhood ACT (r = −0.51: p < 0.001) was found by Piacentini et al [24] in 47 children with a new 
diagnosis of asthma and not on regular treatment. The same authors failed to find the same significant relationship in 
153 children on current asthma treatment. All our patients were on treatment with inhaled steroids, which are known to 
decrease FENO values in a dose-dependent manner [25].  
The  results  of  our  study  show  that  assessment  of asthma  control,  based  primarily  on  symptoms  evaluation 
through standardized questionnaires, does not reflect airway inflammation as assessed by exhaled NO. Some patients 
had poor asthma control based on ACQ score  with  normal  nitric  oxide  levels.  Probably  in  these subjects 
symptoms could depend on other conditions such as hyperventilation, upper airway disease related to rhinitis and 
CRS, or neutrophilic airway inflammation. Other patients appeared to be controlled according to ACQ, despite 
increased FENO values suggestive of eosinophilic airway inflammation. It is well known that persistent airway 
inflammation may be observed also in patients with asymptomatic asthma [26] possibly leading to airway remodeling 
and fixed bronchial obstruction [27]. It is interesting that most of these patients have  CRSwNP,  comorbidity  which  
has  been  related  to eosinophilic airway inflammation [28].  
In  the  present  study  CRSwNP  was  the  only  asthma comorbidity associated to low nNO values. We suggest 
that combined measurement of FENO  and nNO, which are both easy to obtain in clinical practice, may help clinicians 
to find the patient who may gain advantage to achieve better asthma control from a combined treatment of upper and 
lower airway inflammation [23]. Nasal NO is a valuable objective measurement in monitoring medical and surgical 
therapy for CRS, and increase in nNO has been related to successful  treatment of CRS [18]. 
 While increase in nNO has been shown to correlate with patients’ own perception of improvement of sinusitis, no 
data are available about the correlation between the changes in nNO and the changes in asthma control in patients 
with asthma and CRS.  
A possible limit of this study is that it is a cross-sectional study but we think that it is strengthened by the fact that 
it is a real-life observational study, therefore not influenced by any selection bias.  
In conclusion, our results confirm that nNO is decreased in CRSwNP and show, for the first time, that it is 
negatively related to asthma control, underlying the role of nasal polyposis as an influent comorbidity on asthma control. It 
is conceivable that this biomarker reflects aspects of airway inflammation which are related both to symptoms  
and airway function of asthma, as asthma control was assessed by ACQ, which combines symptoms and FEV1 
scores. 
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